Xenerate AB
http://www.xenerate.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Xenerate AB
CliniGenetics SA
French start-up CliniGenetics SA has devised an integrated pharmacogenomics and bioinformatics technology platform to identify gene and protein targets associated with vascular diseases. The company hopes to use those targets to devise novel therapies and diagnostics.
Start-Up Previews (5/02)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Hospital-Acquired Infections, features profiles of Entomed SA, Infectio Diagnostic Inc., MedMined Inc. and Microbia Inc. Plus these Selected Start-Ups across Health Care: Cardio-optics Inc., Immunocept LLC, Nucleotech LLC and Xenerate AB.
Xenerate AB
By marrying gene therapy with medical device technology, Sweden's Xenerate AB believes it can make implantable vascular devices--artificial grafts and stents--capable of endothelialization, thus improving their biocompatibility and reducing the incidence of intimal hyperplasia, restenosis and other adverse effects.
Company Information
- Industry
-
Biotechnology
- Gene Therapy, Cell Therapy
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice